Bigfoot Biomedical today announced the U.S. Food and Drug Administration (FDA) has issued 510(k) clearance for the Android version of the Bigfoot Unity® Mobile App, a necessary component of the Bigfoot Unity® Diabetes Management System. Given that 41 percent of U.S. smartphone users choose Android devices, this clearance enables expanded access to a large group...
Eli Lilly Cuts Insulin Prices by 70% and Caps Patient Insulin Out-of-Pocket Costs at $35 Per Month
[Ed. note: This post has been updated with a comment from Leonard C. Glass, MD, FACE, senior vice president, Lilly Diabetes and Obesity, Global Medical Affairs, Eli Lilly and Company] Eli Lilly and Company today announced price reductions of 70% for its most commonly prescribed insulins and an expansion of its Insulin Value Program that caps...
Out of Practice: Why Retirement Doesn’t Always Mean You Stop Seeing Patients
The Importance of Symptom Control: A Holistic Approach to Treating Acromegaly
Pro Golfer Azahara Muñoz Shares Her Experience with Hashimoto’s Disease
Endocrine Society Experts Recommend Individualized Approach to Use of Telehealth
Policy perspective explores factors to maximize effectiveness of telehealth Following rapid growth during the COVID-19 pandemic, telehealth visits are expected to remain an important part of endocrine care, according to a new Endocrine Society policy perspective published in The Journal of Clinical Endocrinology & Metabolism. Health care providers need to consider a variety of...
Positive Clinical Data for Oral Treatment of Acromegaly Presented at ENDO
ENDO 2022 saw the presentation of positive clinical data from the open-label extensions (OLEs) of two of the Phase 3 trials of oral octreotide for patients with acromegaly. Amryt is marketing the drug as Mycapssa. Data presented in a late-breaking poster presentation of the 2nd year of the OLE of OPTIMAL (NCT03252353), a randomized, double-blind...